Dyax Announces CEO Transition Plan

Gustav A. Christensen to Succeed Henry E. Blair as President and CEO on January 1, 2009

22-Oct-2008 - USA

Dyax Corp. announced that Gustav A. Christensen, who joined Dyax as Executive Vice President and Chief Business Officer in April 2007, will succeed Henry E. Blair as President and Chief Executive Officer on January 1, 2009. Mr. Blair, who co-founded Dyax in 1989 and has served as Chairman, President and Chief Executive Officer since 1995, will retire and become Chairman of the Board after transitioning his executive role to Mr. Christensen. Mr. Blair and Mr. Christensen will work closely together over the following months to ensure a seamless leadership transition.

Mr. Christensen joined Dyax as Executive Vice President and Chief Business Officer, where he has led the Company's partnering strategy and other business development activities, including licensing and collaboration transactions. He has over 25 years of experience in the biotechnology industry as an officer, director, investor and banker. Mr. Christensen received his master's of science degree in economics from the University of Aarhus (Denmark) and a master's degree in business administration (MBA) from Harvard Business School.

Mr. Blair has been director and officer of Dyax since co-founding the company in 1989. He has over thirty years of experience in the biopharmaceutical industry, co-founding Dyax, Genzyme, Biocode, GelTex Pharmaceuticals and Biotage, the predecessor to Dyax. He has also served as a director of GTC Biotherapeutics, Esperion Therapeutics, Celtrix Pharmaceuticals, and DynaGen. Mr. Blair was also a member of the board of overseers at Tufts University School of Medicine and the Lahey Hitchcock Clinic and a trustee of the Harvard-affiliated Center for Blood Research.

https://www.bionity.com/en/news/88488/dyax-announces-ceo-transition-plan.html